I was delighted to be contacted by ITM AG, a Germany based pharmaceutical company specialising in targeted radionuclide technology in precision oncology (e.g. Peptide Receptor Radionuclide Therapy – PRRT). The company is formally known as ITM Isotopen Technologien München.
One of their pipeline developments is 177Lu-Edotreotide / Solucin® in patients with neuroendocrine tumors of gastroenteric or pancreatic origin (GEP-NET). The development is via the COMPETE Phase III Clinical Trial which is being conducted worldwide in 11 countries at 33 sites and is open for recruitment. I actually wrote about this trial after attending a workshop at the annual ENETS conference in 2018.
I was delighted when they wanted to interview me to see how I was coping 2 years on and particularly during COVID-19.
I embedded the PDF file of the interview below but in case you’re reading on a small device, you can find the file by clicking here.
Disclaimer. Ronny Allan has received no financial payment from ITM AG and the interview or this article does not constitute a recommendation to use any of their products. Furthermore, taking part in a clinical trial is a big decision and must be considered carefully in conjunction with your healthcare professionals and close family.
Thanks for reading